These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 23609947

  • 1. Systemic metabolic abnormalities in adult-onset acid maltase deficiency: beyond muscle glycogen accumulation.
    Pascual JM, Roe CR.
    JAMA Neurol; 2013 Jun; 70(6):756-63. PubMed ID: 23609947
    [Abstract] [Full Text] [Related]

  • 2. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY, Ho CH, Hsieh YH, Kikuchi T.
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [Abstract] [Full Text] [Related]

  • 3. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F, Ding E, Migone F, Serra D, Schneider A, Chen YT, Amalfitano A.
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [Abstract] [Full Text] [Related]

  • 4. Dietary treatment in late-onset acid maltase deficiency.
    Bodamer OA, Leonard JV, Halliday D.
    Eur J Pediatr; 1997 Aug; 156 Suppl 1():S39-42. PubMed ID: 9266214
    [Abstract] [Full Text] [Related]

  • 5. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F, Ding E, Liao SX, Migone F, Dai J, Schneider A, Serra D, Chen YT, Amalfitano A.
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [Abstract] [Full Text] [Related]

  • 6. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease.
    Preisler N, Laforet P, Madsen KL, Hansen RS, Lukacs Z, Ørngreen MC, Lacour A, Vissing J.
    Mol Genet Metab; 2012 Nov; 107(3):462-8. PubMed ID: 22981821
    [Abstract] [Full Text] [Related]

  • 7. Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures.
    Isaacs H, Savage N, Badenhorst M, Whistler T.
    J Neurol Neurosurg Psychiatry; 1986 Sep; 49(9):1011-8. PubMed ID: 3093639
    [Abstract] [Full Text] [Related]

  • 8. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy.
    Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, Martiniuk F.
    Muscle Nerve; 2007 Jan; 35(1):70-7. PubMed ID: 17022069
    [Abstract] [Full Text] [Related]

  • 9. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, Kishnani PS, Millington DS, Bashir MR, Bali DS.
    Am J Med Genet C Semin Med Genet; 2012 Feb 15; 160C(1):50-8. PubMed ID: 22252961
    [Abstract] [Full Text] [Related]

  • 10. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, Brown T, Young SP, Clay TM, Amalfitano A, Chen YT, Koeberl DD.
    Mol Ther; 2005 Nov 15; 12(5):876-84. PubMed ID: 16005263
    [Abstract] [Full Text] [Related]

  • 11. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, Meikle P, Hopwood JJ, Nagashima K, Nagaraju K, Plotz PH.
    Mol Ther; 2005 Jan 15; 11(1):48-56. PubMed ID: 15585405
    [Abstract] [Full Text] [Related]

  • 12. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K, Hopwood JJ, Meikle PJ.
    Clin Chim Acta; 2005 Nov 15; 361(1-2):191-8. PubMed ID: 15993875
    [Abstract] [Full Text] [Related]

  • 13. Delayed or late-onset type II glycogenosis with globular inclusions.
    Sharma MC, Schultze C, von Moers A, Stoltenburg-Didinger G, Shin YS, Podskarbi T, Isenhardt K, Tews DS, Goebel HH.
    Acta Neuropathol; 2005 Aug 15; 110(2):151-7. PubMed ID: 15986226
    [Abstract] [Full Text] [Related]

  • 14. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.
    Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C.
    Clin Chim Acta; 2004 Sep 15; 347(1-2):97-102. PubMed ID: 15313146
    [Abstract] [Full Text] [Related]

  • 15. Late onset glycogen storage disease type II: pitfalls in the diagnosis.
    Papadimas GK, Spengos K, Papadopoulos C, Manta P.
    Eur Neurol; 2012 Sep 15; 67(2):65-8. PubMed ID: 22179097
    [Abstract] [Full Text] [Related]

  • 16. [Lysosomal glycogen storage disease without acid maltase deficiency(Danon disease)].
    Ohno K.
    Ryoikibetsu Shokogun Shirizu; 2000 Sep 15; (29 Pt 4):491-2. PubMed ID: 11032005
    [No Abstract] [Full Text] [Related]

  • 17. Diet composition and the performance of high-intensity exercise.
    Maughan RJ, Greenhaff PL, Leiper JB, Ball D, Lambert CP, Gleeson M.
    J Sports Sci; 1997 Jun 15; 15(3):265-75. PubMed ID: 9232552
    [Abstract] [Full Text] [Related]

  • 18. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S, Danesino C, Pichiecchio A, Repetto A, Poloni GU, Rossi M, Fratino P, Moglia A, Costa A.
    Adv Ther; 2008 Aug 15; 25(8):820-9. PubMed ID: 18704279
    [Abstract] [Full Text] [Related]

  • 19. Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.
    Mobarhan S, Pintozzi RL, Damle P, Friedman H.
    JPEN J Parenter Enteral Nutr; 1990 Aug 15; 14(2):210-2. PubMed ID: 2112630
    [Abstract] [Full Text] [Related]

  • 20. Hepatic glycogen storage disorders: what have we learned in recent years?
    Burda P, Hochuli M.
    Curr Opin Clin Nutr Metab Care; 2015 Jul 15; 18(4):415-21. PubMed ID: 26001652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.